VCBeat Health Contact Us
Home Hengrui Pharma Reports Positive Topline Results from China Phase I First-in-Human Study of HRS-4729, a GLP-1/GIP/GCG Triple Receptor Agonist

Hengrui Pharma Reports Positive Topline Results from China Phase I First-in-Human Study of HRS-4729, a GLP-1/GIP/GCG Triple Receptor Agonist

May 27, 2026 07:00 CST Updated 07:31
Hengrui Pharma

Innovative and High-Quality Pharmaceutical Developer